BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients ...
This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.
Predictions for identifying 1-year seizure recurrence performed significantly better in electroencephalography (EEG) without interictal epileptiform discharges. An automated processing algorithm ...
Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results